Meeting highlights from the Committee for Medicinal Products for Human Use, 20-23 October 2014: Six new medicines recommended for approval

 

London, UK (October 24, 2014) – Six new medicines have been recommended for approval at the October meeting of the Committee for Medicinal Products for Human Use (CHMP), two of which are for orphan conditions. The European Medicines Agency has recommended granting a marketing authorisation under exceptional circumstances for Scenesse (afamelanotide) for the treatment of erythropoietic protoporphyria (EPP), a rare genetic disease which causes intolerance to light. Scenesse is the first medicine for patients with this condition. This type of authorisation is granted to medicines where comprehensive data on the medicine cannot be collected, for example, because the condition is too rare, or because the collection of full information is not possible or is unethical.


During the evaluation of Scenesse, the CHMP invited patients to share their experience of living with this condition. This is the first time that patients have been involved in CHMP discussions on the benefits and risks of a medicine. For more information please see
press release.

 

The CHMP also gave a positive opinion for Lynparza (olaparib), a first-in-class medicine for the treatment of women with a subtype of ovarian cancer for which there are limited treatment options. Lynparza has an orphan designation. For more information please see press release.

 

Duavive (conjugated oestrogens / bazedoxifene) was recommended by the CHMP as a new treatment option for oestrogen deficiency.

 

Rixubis (nonacog gamma) received a positive opinion for the treatment and prophylaxis of bleeding in patients with haemophilia B.

 

The CHMP granted positive opinions for two informed consent applications: Duloxetine Lilly (duloxetine) for the treatment of major depressive disorder, diabetic peripheral neuropathic pain and generalised anxiety disorder, and Paliperidone Janssen (paliperidone) for the treatment of schizophrenia. An informed consent application makes use of data from the dossier of a previously authorised medicine, with the marketing authorisation holder of that medicine giving consent for the use of their data in the application.

Werbung

 

 

Recommendation on extension of therapeutic indication

 

The Committee recommended an extension of indication for Xtandi.

 

 

Outcome of two safety reviews

 

The CHMP has concluded its review of the benefits and risks of Iclusig (ponatinib), a medicine for the treatment of leukaemia, and has recommended strengthened warnings in the product information aimed at minimising the risk of blood clots and blockages in the arteries.

The Committee also reviewed the safety and efficacy of medicines containing the antibiotics colistin or colistimethate sodium (known as polymyxins) and recommended changes to the product information of products for injection or inhalation to ensure their safe and effective use in the treatment of serious infections that are resistant to standard antibiotics.

 

 

Agenda and minutes

 

The agenda of the October 2014 meeting is published on the EMA website. The minutes of the meeting will be published during the week following the November CHMP meeting.

 

 

CHMP statistics

 

Key figures from the October 2014 CHMP meeting are represented in the graphic on the website.

For an overview of all information available from the October CHMP, please click on the below link: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10/news_detail_002191.jsp&mid=WC0b01ac058004d5c1  


European Medicines Agency, 24.10.2014 (tB).

MEDICAL NEWS

COVID-19 pandemic sees increased consults for alcohol-related GI and liver…
The eyes offer a window into Alzheimer’s disease
Ventilating the rectum to support respiration
Screening for ovarian cancer did not reduce deaths
Fatigue, mood disorders associated with post-COVID-19 syndrome

SCHMERZ PAINCARE

Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern
Wenn Schmerzen nach einer OP chronisch werden
Deutscher Schmerz- und Palliativtag 2021 – ONLINE: Schmerzmediziner, Politiker und…
Deutscher Schmerz- und Palliativtag 2021 – ONLINE: COVID-19-Pandemie belastet Schmerzpatienten…

DIABETES

Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…
Minimalinvasive Geräte warnen ungenügend vor Unterzuckerung
Typ-1-Diabetes und Hashimoto-Thyreoiditis treten häufig gemeinsam auf
Risikofaktoren für einen schweren COVID-19-Verlauf bei Menschen mit Diabetes
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ meldet…

ERNÄHRUNG

DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren
Gesundheitliche Auswirkungen des Salzkonsums bleiben unklar: Weder der Nutzen noch…

ONKOLOGIE

Krebs – eine unterschätzte finanzielle Herausforderung
Cannabidiol gegen Hirntumore
Assistierte Selbsttötung bei Krebspatienten: Regelungsbedarf und Ermessensspielraum
Leberkrebs: Bei welchen Patienten wirkt die Immuntherapie?
Konferenzbericht vom virtuellen Münchener Fachpresse-Workshop Supportive Therapie in der Onkologie

MULTIPLE SKLEROSE

Neue S2k-Leitlinie für Diagnostik und Therapie der Multiplen Sklerose
Krankheitsbezogenes Kompetenznetz Multiple Sklerose: Stellungnahme zu SARS CoV 2 Impfdaten…
Schwangere mit MS: Schadet Schubbehandlung dem Ungeborenen?
Multiple Sklerose: Ein Sprung sagt mehr, als viele Kreuzchen auf…
Multiple Sklerose: Salzkonsum reguliert Autoimmunerkrankung

PARKINSON

Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung
Neuer Bewegungsratgeber unterstützt Menschen mit M. Parkinson durch Yoga
Covid-19-Prävention: besondere Vorsicht bei Patienten mit der Parkinson-Krankheit